title: Eradication of Helicobacter pylori in patients with end-stage renal disease under dialysis treatment.
abstract: The efficacy and safety of combination therapy with amoxicillin, lansoprazole, and plaunotol for the eradication of Helicobacter pylori in patients on dialysis were evaluated. The study subjects comprised 15 dialysis patients in whom H pylori had been found in the gastric mucosa. The patients were given 500 mg amoxicillin once a day for 3 weeks, 30 mg lansoprazole once a day for 8 weeks, and 80 mg plaunotol three times a day for 24 weeks. Endoscopy was performed on entry and at 4 and 24 weeks after cessation of amoxicillin. The concentrations of serum gastrin and gastric juice ammonia also were measured. Fourteen patients completed the treatment protocol, one having dropped out because of nausea and diarrhea. H pylori was eradicated in 11 of the 14 patients 4 weeks after the end of amoxicillin therapy (eradication rate, 78.6%). All but one patient was free of H pylori 24 weeks after the amoxicillin was discontinued. Patients who became negative for H pylori had significantly decreased serum gastrin and gastric juice ammonia concentrations. Our findings indicate that a combination of amoxicillin, lansoprazole, and plaunotol can be used to eradicate H pylori in patients on dialysis.
authors.affiliation: Fourth Department of Internal Medicine, Saitama Medical Center, Kawagoe, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Tamura
authors.forename: H
authors.initials: H
authors.lastname: Tokushima
authors.forename: M
authors.initials: M
authors.lastname: Murakawa
authors.forename: O
authors.initials: O
authors.lastname: Matsumura
authors.forename: S
authors.initials: S
authors.lastname: Itoyama
authors.forename: S
authors.initials: S
authors.lastname: Sekine
authors.forename: H
authors.initials: H
authors.lastname: Hirose
authors.forename: T
authors.initials: T
authors.lastname: Mitarai
authors.forename: K
authors.initials: K
authors.lastname: Isoda
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004224:Diterpenes; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005233:Fatty Alcohols / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000378:metabolism / Q000382:microbiology / Q000628:therapy; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D006435:Renal Dialysis; D013997:Time Factors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D004224:Diterpenes; D005233:Fatty Alcohols; D010406:Penicillins; D064747:Lansoprazole; D000658:Amoxicillin; D009853:Omeprazole; C047686:plaunotol